
Hagop Kantarjian/mdanderson.org
Mar 19, 2025, 12:12
Hagop Kantarjian: Expert recommendations on using MRD in ALL
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Expert recommendations on using MRD in ALL now out in Blood Advances.
ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT.”
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Authors: Nicholas J. Short et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 19, 2025, 12:12
Mar 19, 2025, 12:07
Mar 19, 2025, 12:06
Mar 19, 2025, 11:59
Mar 19, 2025, 11:38
Mar 19, 2025, 11:01
Mar 19, 2025, 10:48